

1. Pilarski R. Cowden syndrome: A critical review of the clinical literature. *J Genet Couns* 2009;18:13–27.
2. Hobert JA, Eng C. PTEN hamartoma tumor syndrome: An overview. *Genet Med* 2009;11:687–694.
3. Menko FH, van Steensel MA, Giraud S, et al. Birt-Hogg-Dubé syndrome: Diagnosis and management. *Lancet Oncol* 2009;10:1199–1206.
4. Kruger S, Kinzel M, Walldorf C, et al. Homozygous PMS2 germline mutations in two families with early-onset hematological malignancy, brain tumours, HNPCC-associated tumours, and signs of neurofibromatosis type 1. *Eur J Hum Genet* 2008;16:62–72.
5. Badeloe S, Frank J. Clinical and molecular genetic aspects of hereditary multiple cutaneous leiomyomatosis. *Eur J Dermatol* 2009;19:545–551.
6. Moline J, Eng C. Multiple endocrine neoplasia type 2: An overview. *Genet Med* 2011;13:755–764.
7. Ferner RE. The neurofibromatoses. *Pract Neurol* 2010;10:82–93.
8. Williams VC, Lucas J, Babcock MA, et al. Neurofibromatosis type 1 revisited. *Pediatrics* 2009;123:124–133.
9. Ashagiri AR, Parry DM, Butman JA, et al. Neurofibromatosis type 2. *Lancet Med* 2011;13:755–764.
10. Beggs AD, Latchford AR, Vasen HF, et al. Peutz-Jeghers syndrome: A systematic review and recommendations for management. *Gut* 2010;59:975–986.
11. Borkowska J, Schwartz RA, Kotulska K, et al. Tuberosus sclerosis complex: Tumors and tumorigenesis. *Int J Dermatol* 2011;50:13–20.
12. Winship IM, Dudding TE. Lessons from the skin—cutaneous features of familial cancer. *Lancet Oncol* 2008;9:462–472.
13. Burger B, Cattani N, Trueb S, et al. Prevalence of skin lesions in familial adenomatous polyposis: A marker for presymptomatic diagnosis? *Oncologist* 2011;16:1698–1705.
14. Evans DG, Farndon PA. Nevoid Basal Cell Carcinoma Syndrome. In: Pagon RA, Bird TD, Dolan CR, et al., eds. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 1993. Accessed September 4, 2014.
15. Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. *J Am Acad Dermatol* 2009;61:677e1–677e14.
16. Kremer KH, Di Giovanna JJ. Xeroderma Pigmentosum. In: Pagon RA, Bird TD, Dolan CR, et al., eds. GeneReviews [Internet]. Seattle, WA: University of Washington, Seattle; 1993. Accessed September 4, 2014.
17. The Breast Cancer Linkage Consortium. Cancer risks in BRCA2 mutation carriers. *J Natl Cancer Inst* 1999;91:1310–1316.
18. Dores GM, Curtis RE, Toro JR, et al. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms: Insight into Muir-Torres syndrome. *Cancer* 2008;113:3372–3381.
19. Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: Genetic and genomic testing for cancer susceptibility. *J Clin Oncol* 2010;28:893–901.
20. Hemminki K, Eng C. Clinical genetic counselling for familial cancers requires reliable data on familial cancer risks and general action plans. *J Med Genet* 2004;41:801–807.
21. Goldstein AM, Chidambaram A, Halpern A, et al. Rarity of CDK4 germline mutations in familial melanoma. *Melanoma Res* 2002;12:51–55.
22. Hayward NK. Genetics of melanoma predisposition. *Oncogene* 2003;22:3053–3062.
23. Goldstein AM, Chan H, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. *Cancer Res* 2006;66:9818–9828.
24. Newton Bishop JA, Bataille V, Pinney E, et al. Family studies in melanoma: Identification of the atypical mole syndrome (AMS) phenotype. *Melanoma Res* 1994;4:199–206.
25. Newton Bishop JA, Gruis NA. Genetics: What advice for patients who present with a family history of melanoma? *Semin Oncol* 2007;34:452–459.
26. Bishop JN, Harland M, Randerson-Moor J, et al. Management of familial melanoma. *Lancet Oncol* 2007;8:46–54.
27. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations in melanoma. *J Natl Cancer Inst* 2002;94:894–903.
28. Begg CB, Orlow I, Hummer AJ, et al. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. *J Natl Cancer Inst* 2005;97:1507–1515.
29. Demenais F, Mohamdi H, Chaudru V, et al. Association of MC1R variants and host phenotypes with melanoma risk in CDKN2A mutation carriers: A GenoMEL study. *J Natl Cancer Inst* 2010;102:1568–1583.
30. Raimondi S, Sera F, Gandini S, et al. MC1R variants, melanoma and red hair color phenotype: A meta-analysis. *Int J Cancer* 2008;122:2753–2760.
31. de Snoo FA, Bishop DT, Bergman W, et al. Increased risk of cancer other than melanoma in CDKN2A founder mutation (p16-Leiden)—positive melanoma families. *Clin Cancer Res* 2008;14:7151–7157.
32. Randerson-Moor JA, Harland M, William S, et al. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family. *Hum Mol Genet* 2001;10:55–62.
33. Tsao H, Zhang X, Kwitkowski K, et al. Low prevalence of germline CDKN2A and CDK4 mutations in patients with early-onset melanoma. *Arch Dermatol* 2000;136:1118–1122.
34. Berg P, Wennberg AM, Tuominen R, et al. Germline CDKN2A mutations are rare in child and adolescent cutaneous melanoma. *Melanoma Res* 2004;14:251–255.
35. Aspinwall LG, Leaf SL, Kohlmann W, et al. Patterns of photoprotection following CDKN2A/p16 genetic test reporting and counseling. *J Am Acad Dermatol* 2009;60:745–757.
36. Aspinwall LG, Leaf SL, Dola ER, et al. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. *Cancer Epidemiol Biomarkers Prev* 2008;17:1510–1519.
37. Eckerle Mize D, Bishop M, Reese E, et al. Familial Atypical Multiple Mole Melanoma Syndrome. In: Riegert-Johnson DL, Boardman LA, Heffernan T, Roberts M, eds. Cancer Syndromes [Internet]. Bethesda, MD: National Center for Biotechnology Information (US); 2009. Accessed September 3, 2014.
38. Bartsch DK, Sina-Frey M, Lang S, et al. CDKN2A germline mutations in familial pancreatic cancer. *Ann Surg* 2002;236:730–737.
39. Verna EC, Hwang C, Stevens PD, et al. Pancreatic cancer screening in a prospective cohort of high-risk patients: A comprehensive strategy of imaging and genetics. *Clin Cancer Res* 2010;16:5028–5037.
40. Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). *Orphanet J Rare Dis* 2008;3:32.
41. Tom WL, Hurley MY, Oliver DS, et al. Features of basal cell carcinomas in basal cell nevus syndrome. *Am J Med Genet A* 2011;155A:2098–2104.
42. Evans DG, Howard E, Giblin C, et al. Birth incidence and prevalence of tumor-prone syndromes: Estimates from a UK family genetic register service. *Am J Med Genet A* 2010;152A:327–332.
43. Lupi O. Correlations between the sonic hedgehog pathway and basal cell carcinoma. *Int J Dermatol* 2007;46:1113–1117.
44. Yamamoto K, Yoshihashi H, Furiya N, et al. Further delineation of 9q22 deletion syndrome associated with basal cell nevus (Gorlin) syndrome: Report of two cases and review of the literature. *Congenit Anom (Kyoto)* 2009;49:8–14.
45. Pastorino L, Ghiorzo P, Nasti S, et al. Identification of a SUFU germline mutation in a family with Gorlin syndrome. *Am J Med Genet A* 2009;149A:1539–1543.
46. Fan Z, Li J, Du J, et al. A missense mutation in PTCH2 underlies dominantly inherited NBCCS in a Chinese family. *J Med Genet* 2008;45:303–308.
47. Go JW, Kim SH, Yi SY, et al. Basal cell nevus syndrome showing several histologic types of Basal cell carcinoma. *Ann Dermatol* 2011;23:S36–S40.
48. Kimonis VE, Mehta SG, Digiovanna JJ, et al. Radiological features in 82 patients with nevoid basal cell carcinoma (NBCC or Gorlin) syndrome. *Genet Med* 2004;6:495–502.
49. Amalshah SF, Riffaud L, Brassier G, et al. Nevoid basal cell carcinoma syndrome: Relation with desmoplastic medulloblastoma in infancy. A population-based study and review of the literature. *Cancer* 2003;98:618–624.
50. Mohtasham N, Nemati S, Jamshidi S, et al. Odontogenic keratocysts in nevoid basal cell carcinoma syndrome: A case report. *Cases J* 2009;2:93–99.
51. Ball A, Wenning J, Van Eyk N. Ovarian fibromas in pediatric patients with basal cell nevus (Gorlin) syndrome. *J Pediatr Adolesc Gynecol* 2011;24:e5–e7.
52. Bossert T, Walther T, Vondryš D, et al. Cardiac fibroma as an inherited manifestation of nevoid basal-cell carcinoma syndrome. *Tex Heart Inst J* 2006;33:88–90.
53. Bree AF, Shah MR. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). *Am J Med Genet A* 2011;155A:2091–2097.
54. Takahashi C, Kanazawa N, Yoshikawa Y, et al. Germline PTCH1 mutations in Japanese basal cell nevus syndrome patients. *J Hum Genet* 2009;54:403–408.
55. Casaroto AR, Loures DC, Moreschi E, et al. Early diagnosis of Gorlin-Goltz syndrome: Case report. *Head Face Med* 2011;7:2.
56. Morse CB, McLaren JF, Roy D, et al. Ovarian preservation in a young patient with Gorlin syndrome and multiple bilateral ovarian masses. *Fertil Steril* 2011;96:e47–e50.
57. Boyd KP, Korf BR, Theos A. Neurofibromatosis type 1. *J Am Acad Dermatol* 2009;61:1–14.
58. Yohay K. Neurofibromatosis types 1 and 2. *Neurologist* 2006;12:86–93.
59. Radtke HB, Sebold CD, Allison C, et al. Neurofibromatosis type 1 in genetic counseling practice: Recommendations of the National Society of Genetic Counselors. *J Genet Couns* 2007;16:387–407.
60. Ahmad S, ed. *Neurodegenerative Diseases*. Vol. 724. New York: Landes Bioscience and Springer Science+Business Media; 2012.
61. Patil S, Chamberlain RS. Neoplasms associated with germline and somatic NF1 gene mutations. *Oncologist* 2012;17:101–116.
62. Kossler N, Stricker S, Rödelsperger C, et al. Neurofibromin (Nf1) is required for skeletal muscle development. *Hum Mol Genet* 2011;20:2697–2709.
63. Friedman J. Neurofibromatosis 1. June 2, 2009. <http://www.ncbi.nlm.nih.gov/books/NBK1109/>. Accessed March 6, 2012.

64. Arden-Holmes SL, North KN. Therapeutics for childhood neurofibromatosis type 1 and type 2. *Curr Treat Options Neurol* 2011;13:529–543.
65. Ponder MMF, Hallowell N, Statham H, et al. Genetic counseling, reproductive behavior and future reproductive intentions of people with neurofibromatosis type 1 (NF1). *J Genet Couns* 1998;7:331–344.
66. Evans DG. Neurofibromatosis type 2 (NF2): A clinical and molecular review. *Orphanet J Rare Dis* 2009;4:16.
67. Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. *J Neurooncol* 2010;99:341–347.
68. Baser ME, Friedman JM, Joe H, et al. Empirical development of improved diagnostic criteria for neurofibromatosis 2. *Genet Med* 2011;13:576–581.
69. Evans DG, Raymond FL, Barwell JG, et al. Genetic testing and screening of individuals at risk of NF2. *Clin Genet* 2012;82:416–424.